Abstract
Sorafenib, an antiangiogenic drug, has been introduced for treatment of disseminated renal cell cancer (RCC), a tumor that is radioresistant. We report a case of 51-year-old patient with disseminated RCC who received 30 Gy per ten fractions of radiotherapy (RT) for a single brain metastasis. While the brain metastasis remained stable, the patient had to receive interferon-alpha and later sorafenib due to progression of his extra-cerebral metastases. During sorafenib therapy, complete remission of the cerebral lesion and excellent partial remission of the extra-cerebral metastases were observed. Meanwhile, the patient developed a second cerebral metastasis, which was irradiated only with 20 Gy per ten fractions during a short break in the sorafenib treatment. The follow-up computed tomographies revealed complete remission of the second metastasis and development of brain necrosis in a moderately irradiated area. The case of this patient being his own control demonstrates sorafenib-mediated potentiation of RT effects both in tumor and normal tissues.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
